Your English writing platform
Discover LudwigSuggestions(5)
Exact(2)
Other investigators [133] have suggested a dysfunction of the nigrostriatal dopaminergic pathway that may account for the development of BMS.
In addition, adding trastuzumab did not affect the development of BMs in HER2-overexpressing breast cancer, which is associated with the poor penetration of trastuzumab across the blood-brain barrier (BBB) and poor activity in BMs.
Similar(58)
The median time from initial breast cancer diagnosis to the development of BM was 32.24 months.
Time to BM was defined as the interval from initial breast cancer diagnosis until the development of BM 7, 14.
We therefore investigated the effect of a naturally occurring RSK inhibitor, SL0101 [34], on development of BM- and FL-derived MKs.
The median time from the diagnosis of breast cancer until the development of BM was 32.24 months (range: 0 206.22 months).
Therefore, a more precise definition of patients and breast cancer subtypes at high risk for early development of BM is needed (Heitz et al, 2009).
The development of BM between the two treatment groups was significantly different (37.8% for post-T vs 25.0% for pre-T, P=0.028).
For example, women diagnosed with breast cancer in 1997 2001 had 10 14 years (1998 2011) for their development of BM, whereas women diagnosed with breast cancer in 2007 2011 had <1 to 4 years (2008 2011) for the development of BM.
Apart from triple-negative or HER-2-positive disease, established risk factors for the development of BM are young age at first diagnosis, presence of lung metastases and short disease-free interval (Weil et al, 2005).
These findings suggest that divergent evolution of a selected set of genes played a role in the development of Bm and Bp as effective pathogens and Bt as a non-pathogenic soil saprophyte.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com